NASDAQ:ADRO Aduro Biotech (ADRO) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free ADRO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.28▼$14.6052-Week Range N/AVolume171,500 shsAverage Volume162,237 shsMarket Capitalization$236.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aduro Biotech alerts: Email Address Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About Aduro Biotech Stock (NASDAQ:ADRO)Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Read More Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! ADRO Stock News HeadlinesFebruary 24, 2024 | morningstar.comAduro Clean Technologies Inc Ordinary SharesJanuary 3, 2024 | morningstar.comPT Adaro Energy Indonesia TbkApril 24, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”December 2, 2023 | morningstar.comPT Adaro Energy Indonesia Tbk ADRONovember 16, 2023 | benzinga.comLegend Biotech Stock (NASDAQ:LEGN), Analyst Ratings, Price Targets, PredictionsNovember 10, 2023 | seekingalpha.comBret JensenNovember 6, 2023 | reuters.comConcord Biotech LtdJune 26, 2023 | thestreet.comAduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage StudyApril 24, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”March 18, 2023 | finance.yahoo.comFrench biotech Sensorion does not expect any impact to its liquidity from SVB's closureMarch 15, 2023 | reuters.comSVB shock could have chilling effect on British biotech sectorMarch 15, 2023 | cnbc.comSVB fallout: The impacts on the biotech sectorDecember 17, 2022 | thestreet.comCancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO DebutNovember 30, 2022 | finance.yahoo.comAduro Selected for Shell GameChanger ProgramOctober 29, 2022 | barrons.comMerck’s CFO Says Biotech Deals are Getting DoneSeptember 28, 2022 | finance.yahoo.comPT Adaro Energy Indonesia Tbk (ADRO.JK)July 31, 2021 | barrons.comAdaro EnergySee More Headlines Receive ADRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/04/2020Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ADRO CUSIPN/A CIK1435049 Webwww.aduro.com Phone(206) 485-7051FaxN/AEmployees152Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,370,000.00 Net Margins-230.92% Pretax MarginN/A Return on Equity-101.73% Return on Assets-22.35% Debt Debt-to-Equity RatioN/A Current Ratio8.91 Quick Ratio8.91 Sales & Book Value Annual Sales$17.26 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / BookN/AMiscellaneous Outstanding Shares16,212,000Free FloatN/AMarket Cap$236.61 million OptionableOptionable Beta0.40 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesEric L. DobmeierChairman, President & Chief Executive OfficerAlan GlicklichChief Medical OfficerKirk D. SchumacherSenior Vice President & General CounselTom FrohlichChief Business OfficerNoopur LiffickVP-Investor Relations & Corporate CommunicationsKey Competitors2seventy bioNASDAQ:TSVTAC ImmuneNASDAQ:ACIU23andMeNASDAQ:MEAldeyra TherapeuticsNASDAQ:ALDXVerastemNASDAQ:VSTMView All Competitors ADRO Stock Analysis - Frequently Asked Questions How were Aduro Biotech's earnings last quarter? Aduro Biotech, Inc. (NASDAQ:ADRO) released its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to analysts' expectations of $8.81 million. Aduro Biotech had a negative trailing twelve-month return on equity of 101.73% and a negative net margin of 230.92%. What other stocks do shareholders of Aduro Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Nabriva Therapeutics (NBRV), Amarin (AMRN), Anavex Life Sciences (AVXL), Micron Technology (MU), VBI Vaccines (VBIV) and PTC Therapeutics (PTCT). When did Aduro Biotech IPO? Aduro Biotech (ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. This page (NASDAQ:ADRO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aduro Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.